Angiotensin receptor blockers and risk of myocardial infarction: Systematic review

British Medical Journal

Volumn 331, Issue 7521, 2005, Pages 873-876

  McDonald, Michael A ^a   Simpson, Scot H ^b   Ezekowitz, Justin A ^b   Gyenes, Gabor ^b   Tsuyuki, Ross T ^b  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DIABETES MELLITUS; DRUG SAFETY; EMBASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY DISEASE; MEDLINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; AGED; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTROLLED CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 26944481628     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38595.518542.3A     Document Type: Review

References (28)

1. Levy BI. Can angiotensin II type II receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004;109:8-13.
2. Swedberg K, McMurray JJV. Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT? Eur Heart J 2004;25:357-8.
3. McMurray JJV. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart 2001;86:97-103.
4. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
5. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
6. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
7. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329:1248-9.
8. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double- blind intervention trial. J Hypertens 2003;21:875-86.
9. Bakris G, Sica D, Ram V, Pagan T, Vaitkus PT, Anders RJ. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens 2002;15:53-7.
10. Haneda M, Kikkawa R, Sakai H, Kawamori R. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 2004;66:87-95.
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:961-9.
12. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-9.
13. Matsumori A, on behalf of the assessment of response to candesartan in heart failure in Japan (ARCH-J) study investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003;5:669-77.
14. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
15. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 2003;362:772-6.
16. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003;362:777-81.
17. Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000;139:609-17.
18. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
19. Targum SL, Hung HMJ. Medical-statistical review: NDA 20-665/SE1-016 and 21-283/SE-001 Diovan (valsartan) capsules and tablets. 2001. www.fda.gov/cder/foi/nda/2002/21-283S001_Diovan_medr_P3.pdf (accessed 2 Apr 2005).
20. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.
21. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-52.
22. Willenheimer R, Helmers C, Pantev E, Rydberg E, Lofdahl P, Gordon A, for the Heart Failure Valsartan Exercise Capacity Evaluation (HEAVEN) Study Group. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol 2002;85:261-70.
23. Dunselman PHJM. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol 2001;77:131-8.
24. Di Pasquale P, Bucca V, Scalzo S, Cannizzaro S, Giubilato A, Paterna S. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. Heart 1999;81:606-11.
25. Spinar J, Vitovec J, Spinarova L, Pluhacek L, Fischerova B, Toman J. A comparison of intervention with losartan or captopril in acute myocardial infarction. Eur J Heart Fail 2000;2:91-100.
26. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, and their combination in congestive heart failure. The randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-64.
27. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004;141:693-704.
28. ONTARGET/TRANSCEND Investigators. Rationale, design, and base-line characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global end-point trial/telmisartan randomized assessment study in ace intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61.